This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

News

21Nov 2018

Back to News overview

Cancer researcher Rene Bernards and his team have been awarded a $1 million grant

Cancer Researcher Rene Bernards and his team have been awarded a $1 million grant by the new 'Pancreatic Cancer Collective',  a strategic partnership of the Lustgarten Foundation and Stand Up To Cancer (SU2C).

In a preclinical study, Bernards' team will test a combination of SHP2 inhibitors and MEK inhibitors for the treatment of KRAS-mutant pancreatic cancer patients.  Emile Voest , together with Hana Algül of Technical University Munich, is to lead the clinical study that will be conducted in a later stage.

The Team has discovered that that tumors carrying an activating KRAS mutation are sensitive to the inhibition of SHP2, a protein that helps the transmission of the growth-promoting signal from the cell surface receptors. Moreover, the team has found that SHP2 inhibitors cooperate with inhibitors of MEK, a key RAS downstream effector, to achieve better control of tumor growth. Given these findings, the researchers have proposed a combination of SHP2 inhibitors and MEK inhibitors for the treatment of KRAS-mutant pancreatic cancer patients.

Read more
More about the 7 projects

Share this page